Populära just nu
Redeye adjusts the Fair value range and Base case after the outcome of the rights issue has been con...
Core objectives, including divestments and securing bond refinancing completed One new divestment an...
Möter relativt lätta jämförelsetal BTS möter relativt enkla jämförelsetal i Q1’24.
Redeye had a conversation with the founders of Strax after the latest divestments of Clickr to Matte...
Redeye takes a positive stance towards Avensia’s ambitious yet reasonable financial targets.
Redeye comments on the phase I biodistribution study with laquinimod eye drops and why it is importa...
Redeye views today's press release from Lifecare positively, announcing that it has reached the targ...
Redeye comments on events in the fourth quarter report, including progress with bacterial vaccine pr...
Redeye comments on the news that Annexin has announced a rights issue of up to SEK45m.
Nettoomsättningen uppgick till 62,0 MSEK (59,0) i det tredje kvartalet (november-januari) i Purefuns...
- Confirms a long-term obesity and diabetes device contract - No material impact next 2Y, ~SEK 700m ...
Redeye updates its estimates for the Q1 2024 report (due 2024-04-25).
Redeye retains its positive view on Hexatronic and keeps its outlook for Hexatronic regarding Q1 and...
Redeye comments on Ngenic’s intention to divest its subsidiary Ngenic Sweden AB to Nordic Propeye fo...
Redeye takes a positive view of CombinedX’s most recent acquisition Why.
